search icon

    Market Snapshot

    • S&P Futures


    • Dow Futures


    • Nasdaq Futures


    blog search icon

    Immunome, Inc. (IMNM) Stock Skyrockets Following Promising Results of IMM-BCP-01 in Neutralizing Delta Variant of Covid-19

    By ST Staff

    Jul 20,2021

    8:42 AM UTC

    Immunome, Inc. (IMNM) stock prices soared by 20.85% shortly after market trading commenced on July 20th, 2021, bringing the price per share up to USD$20.11 early on in the trading day.


    July 20th, 2021 saw the company announced the potent neutralizing activity demonstrated by its three-antibody cocktail (IMM-BCP-01) against the Delta variant of the coronavirus pandemic. The treatment also showed in-vitro activity via non-neutralizing mechanics, such as complement fixation, which the company anticipates enabling viral clearance for the treatment.

    Addressing Delta Variant Concerns

    With the highly concerning evolution of the Covid-19 virus taking the world by storm, the company is hopeful that its drug candidate is adequately positioned to become a leader in the global fight against the deadly coronavirus. The treatment’s ability to maintain neutralizing activity against the newer Covid-19 variants is highly promising, with its mechanisms of action targeting at least three non-overlapping epitopes. The mechanisms are informed by an authentic human immune response and provide a robust defense against future mutational drift.

    Expediting Development

    With the majority of the current cases in the United States reporting infection with the Delta variant of the coronavirus, the company was awarded USD$17.6 million as a technology award to aid the development of the treatment. Granted by the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense in collaboration with the Defense Health Agency, the award serves to accelerate the availability of the treatment as the world hurtles towards universal immunizations.

    Ahead of the Curve

    With cases finally dwindling down, the United States is on high alert for the near-term potential for a resurgence of coronavirus infections, as a result of the emerging variants. The company is exploring all options to expedite the development of IMM-BCP-01, with plans to submit an IND application with the U.S Food and Drug Administration as early as this quarter. The biopharmaceutical company leverages its proprietary human memory B cell platform in a bit to aid the discovery and development of first-in-class antibody therapeutics.

    Future Outlook for IMNM

    Armed with a promising drug candidate that could address the massive gap that arose in the marketspace as a result of the proliferation of the Delta variant, IMNM is poised to capitalize on the expanded scope of the opportunities afforded to it. Investors are hopeful that management will be able to spearhead the commercialization and proliferation of IMM-BCP-01, thus resulting in increases in shareholder value over the long term.

    More From Stocks telegraph